Q-omics provides the consensus-scored RPL24P7 profile across patient tissues and cancer cell-line models. RPL24P7 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, RPL24P7 is differentially expressed in 6, with the highest sampling consensus in COAD. Additionally, RPL24P7 RNA expression shows 9,711 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight KICH, COAD, and DLBC as cancer lineages where RPL24P7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL24P7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL24P7 survival associations across molecular data types. RPL24P7 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL24P7 RNA expression–survival associations across cancer types. High RPL24P7 expression shows unfavorable associations in KICH, but favorable associations in CESC, SKCM, READ, COAD and BLCA. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify KICH as the clearest survival context for RPL24P7 RNA expression.
This table summarizes RPL24P7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RPL24P7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL24P7 shows higher tumor expression in COAD, ESCA, LIHC, PRAD, KIRC and KIRP. The COAD box plot shows higher RPL24P7 RNA expression in tumor versus normal tissue (log2 FC = +0.585, t-test p < 0.001).
This table shows molecular features associated with RPL24P7 in patient tissues and cancer cell lines. In patient samples, RPL24P7 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
